Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cost-Utility of Fingolimod Compared With Dimethyl Fumarate (Dmf) In Highly Active Relapsing Remitting Multiple Sclerosis (Rrms) In England: Comparison of A Markov and Discrete Event Simulation Model.
The Neuroprotective Effect of the Association of Aquaporin-4/Glutamate Transporter-1 against Alzheimer's Disease.
Vestibular and ocular motor function prior to and after therapeutic apheresis with small plasmafilter in multiple sclerosis.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.
The Stress-Buffering Effects of Hope on Adjustment to Multiple Sclerosis.
A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in khuzestan, iran.
The Challenges, Advantages, and Future of Phenome-Wide Association Studies.
No evidence of human herpesvirus DNA in the CSF of multiple sclerosis patients.
Multiple sclerosis: overview of disease-modifying agents.
Promoting peripheral myelin repair.
Translation, Cultural Adaptation and Validation of the Qualiveen-30 Questionnaire in Persian for Patients with Spinal Cord Injury and Multiple Sclerosis.
Assessment of cortical damage in early multiple sclerosis with quantitative T2 relaxometry.
Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.
Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis.
[Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
A spring to summer shift of pro-inflammatory cytokine production in multiple sclerosis patients.
Reversed takotsubo cardiomyopathy in a patient with new-onset multiple sclerosis: Cause, link, or just coincidence?
Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report.
Adjudin - a Male Contraceptive with Other Biological Activities.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.
Neuromyelitis optica.
Development and implementation of microsimulation models of neurological conditions.
Automated brain volumetrics in multiple sclerosis: a step closer to clinical application.
Pages
« first
‹ previous
…
638
639
640
641
642
643
644
645
646
…
next ›
last »